Lean MASLD represents a distinct phenotype with milder histologic disease but similar clinical outcomes compared with overweight/obese MASLD, and the FIB-4 demonstrated lower accuracy for predicting advanced fibrosis in lean vs overweight/obese MASLD.
L. de Avila, K. Al-Naamani, M. Papatheodoridi et al.· Journal of the American Medi...· 1 citation
By automatically integrating and interpreting the dynamics of non-invasive tests of liver fibrosis, JLCM enables the personalised prediction of the risk of hard outcomes, rather than the imperfect evaluation of histological surrogates.
C. Moreau, M. Roux, J. Riou et al.· Clinical Gastroenterology an...· 1 citation
This study identifies KIF13B as a novel regulator of hepatic lipid homeostasis in ALD via the KIF13B-KPNA2-PPARα axis, enhancing KPNA2 mediated nuclear import, particularly in combination with PPARα activation, represents a promising therapeutic strategy for ALD.
Kai-Kai Lu, Si Mei, Lian-Xing Zhang et al.· Gut· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.